JP2020517707A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517707A5 JP2020517707A5 JP2019558443A JP2019558443A JP2020517707A5 JP 2020517707 A5 JP2020517707 A5 JP 2020517707A5 JP 2019558443 A JP2019558443 A JP 2019558443A JP 2019558443 A JP2019558443 A JP 2019558443A JP 2020517707 A5 JP2020517707 A5 JP 2020517707A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pharmaceutically acceptable
- treatment
- item
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 10
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000011519 second-line treatment Methods 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 239000003981 vehicle Substances 0.000 claims 2
- 238000000034 method Methods 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Chemical group 0.000 description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 229910052717 sulfur Chemical group 0.000 description 6
- 239000011593 sulfur Chemical group 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 229920006395 saturated elastomer Chemical group 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- -1 1H-pyrrolill Chemical group 0.000 description 1
- VZWOXDYRBDIHMA-UHFFFAOYSA-N 2-methyl-1,3-thiazole Chemical compound CC1=NC=CS1 VZWOXDYRBDIHMA-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 1
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 206010072930 Mucolipidosis type IV Diseases 0.000 description 1
- 102100026502 Mucolipin-1 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762490280P | 2017-04-26 | 2017-04-26 | |
| US62/490,280 | 2017-04-26 | ||
| PCT/US2018/029288 WO2018200625A1 (en) | 2017-04-26 | 2018-04-25 | Modulators of sestrin-gator2 interaction and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517707A JP2020517707A (ja) | 2020-06-18 |
| JP2020517707A5 true JP2020517707A5 (enExample) | 2021-07-29 |
| JP7179015B2 JP7179015B2 (ja) | 2022-11-28 |
Family
ID=63920059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019558443A Active JP7179015B2 (ja) | 2017-04-26 | 2018-04-25 | Ｓｅｓｔｒｉｎ－ＧＡＴＯＲ２相互座用のモジュレーターおよびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10912750B2 (enExample) |
| EP (2) | EP4556069A3 (enExample) |
| JP (1) | JP7179015B2 (enExample) |
| CN (2) | CN116370448A (enExample) |
| AU (2) | AU2018258355B2 (enExample) |
| CA (1) | CA3061611A1 (enExample) |
| ES (1) | ES3040534T3 (enExample) |
| TW (1) | TWI776886B (enExample) |
| WO (1) | WO2018200625A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3364958T1 (sl) | 2015-10-23 | 2023-05-31 | Navitor Pharmaceuticals, Inc. | Modulatorji interakcije sestrina in gator2 ter njihova uporaba |
| WO2018200625A1 (en) * | 2017-04-26 | 2018-11-01 | Navitor Pharmaceuticals, Inc. | Modulators of sestrin-gator2 interaction and uses thereof |
| EP3870158A4 (en) | 2018-10-24 | 2022-08-10 | Navitor Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
| CN112969687B (zh) | 2018-10-30 | 2024-08-23 | 吉利德科学公司 | 作为α4β7整合素抑制剂的喹啉衍生物 |
| ES3003232T3 (en) | 2018-10-30 | 2025-03-10 | Gilead Sciences Inc | Compounds for inhibition of alpha4beta7 integrin |
| ES2987796T3 (es) | 2018-10-30 | 2024-11-18 | Gilead Sciences Inc | Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias |
| CA3114240C (en) | 2018-10-30 | 2023-09-05 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
| CN111689993B (zh) * | 2019-03-11 | 2023-04-14 | 凯特立斯（深圳）科技有限公司 | 一种新的含硼类佐米药物关键中间体手性α-氨基硼酸酯的制备方法 |
| CN114222730B (zh) | 2019-08-14 | 2024-09-10 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
| TWI870497B (zh) * | 2019-11-01 | 2025-01-21 | 美商奈維特製藥公司 | 使用mtorc1調節劑的治療方法 |
| CN113876784B (zh) * | 2021-09-27 | 2023-07-21 | 潍坊博创国际生物医药研究院 | 硼代亮氨酸类化合物的新用途 |
| CN115927459A (zh) * | 2022-07-19 | 2023-04-07 | 华南农业大学 | 猪ctns基因在促进动物骨骼肌生长中的应用 |
| EP4612120A1 (en) * | 2022-11-01 | 2025-09-10 | Navitor Pharmaceuticals, Inc. | Modulators of mtorc1 activity and uses thereof |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4110368A (en) | 1972-07-24 | 1978-08-29 | American Cyanamid Company | Hydro substituted prostanoic acids and esters |
| US4346110A (en) * | 1981-06-01 | 1982-08-24 | Merrell Toraude Et Compagnie | Method for treating depression |
| JPS61149964A (ja) | 1984-12-25 | 1986-07-08 | Canon Inc | 電子写真感光体 |
| US4670196A (en) | 1985-09-05 | 1987-06-02 | Norton Company | Tower packing element |
| ES2029799T3 (es) | 1986-01-24 | 1992-10-01 | Toray Industries, Inc. | Derivados de 2,5,6,7 tetranor-4,8-inter-m-fenilen pg12. |
| GB8827885D0 (en) | 1988-11-30 | 1989-01-05 | Wellcome Found | Novel heterocyclic pesticidal compounds |
| US5639600A (en) | 1994-08-05 | 1997-06-17 | The Regents Of The University Of California | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
| DE19623142A1 (de) | 1996-06-10 | 1997-12-11 | Huels Chemische Werke Ag | Enantiomerenangereicherte, durch einen tertiären Kohlenwasserstoffrest substituierte Malonsäuremonoester sowie deren Herstellung |
| WO1998008853A1 (en) * | 1996-08-28 | 1998-03-05 | The Procter & Gamble Company | Phosphinic acid amides as matrix metalloprotease inhibitors |
| US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
| AU3459999A (en) | 1998-04-27 | 1999-11-16 | Warner-Lambert Company | Substituted diarylalkyl amides as calcium channel antagonists |
| CN1146585C (zh) | 1998-11-04 | 2004-04-21 | 蒙特尔技术有限公司 | 用于烯烃聚合的催化剂组分和催化剂 |
| US6329546B1 (en) | 1999-01-12 | 2001-12-11 | Laboratory Of Molecular Biophotonics | Caged amino acids |
| US20030203900A1 (en) | 1999-05-18 | 2003-10-30 | Martin Quibell | Cysteine protease inhibitors |
| HRP20020025A2 (en) | 1999-06-10 | 2003-12-31 | Warner Lambert Co | Mono- and disubstituted 3-propyl gamma-aminobutyric acids |
| US20020155170A1 (en) * | 2000-11-30 | 2002-10-24 | Walsh William John | Nutrient supplements and methods for treating autism and for preventing the onset of autism |
| JP5076257B2 (ja) | 2001-02-01 | 2012-11-21 | 旭硝子株式会社 | 撥水性組成物、表面処理された基材、その製造方法および輸送機器用物品 |
| PT1389617E (pt) | 2001-04-27 | 2007-04-30 | Zenyaku Kogyo Kk | Composto heterocíclico e agente antitumoral contendo o mesmo como igrediente activo |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| EP2055310B1 (en) | 2002-08-14 | 2015-12-16 | Silence Therapeutics GmbH | Protein kinase N beta for the diagnosis and the treatment of late stage tumor |
| US6787664B2 (en) | 2002-09-17 | 2004-09-07 | Warner-Lambert Company Llc | Process for preparing single enantiomers of 5,5,5,5′,5′,5′-hexafluoroleucine and protected analogs |
| AU2002953255A0 (en) | 2002-12-11 | 2003-01-02 | Cytopia Research Pty Ltd | Protein kinase inhibitors |
| EP1611119A1 (en) | 2003-04-03 | 2006-01-04 | Semafore Pharmaceuticals, Inc. | Pi-3 kinase inhibitor prodrugs |
| PT1644363E (pt) | 2003-05-30 | 2012-05-18 | Gemin X Pharmaceuticals Canada Inc | Compostos tri-heterocíclicos, composições e métodos para tratamento de cancro ou doenças virais |
| EP2371835A1 (en) | 2003-07-03 | 2011-10-05 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| ES2607804T3 (es) | 2004-05-13 | 2017-04-04 | Icos Corporation | Quinazolinones como inhibidores de la fosfatidilinositol humana 3-quinasa delta |
| US20070212428A1 (en) * | 2004-06-04 | 2007-09-13 | Mood Management Sciences, Inc. | Methods and compositions for treating mood disorder |
| DE102004053407A1 (de) | 2004-11-05 | 2006-05-11 | Bayer Healthcare Ag | Acylierte Nonadepsipeptide II |
| EP1856135B1 (en) | 2005-01-19 | 2009-12-09 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| AU2006242851A1 (en) | 2005-02-18 | 2006-11-09 | Centre National De La Recherche Scientifique (C.N.R.S.) | Diastereoisomers of 4-hydroxyisoleucine and uses thereof |
| TWI337608B (en) | 2005-05-12 | 2011-02-21 | Abbott Lab | Apoptosis promoters |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| RS53627B1 (sr) | 2005-10-07 | 2015-04-30 | Exelixis Inc. | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova upotreba kao inhibitora fosfatidilinozitol3-kinaze |
| DK1951684T3 (en) | 2005-11-01 | 2016-10-24 | Targegen Inc | BIARYLMETAPYRIMIDIN kinase inhibitors |
| DK3184526T3 (en) | 2005-12-13 | 2019-01-14 | Incyte Holdings Corp | PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| BRPI0710874A2 (pt) | 2006-04-26 | 2012-02-14 | Hoffmann La Roche | compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos |
| US20100093706A1 (en) * | 2006-08-21 | 2010-04-15 | Prexa Pharmaceuticals, Inc. | Multimediator transporter inhibitors for use in treatment of central nervous system disorders |
| SG166093A1 (en) | 2006-09-22 | 2010-11-29 | Pharmacyclics Inc | Inhibitors of brutonæs tyrosine kinase |
| KR20130095850A (ko) | 2006-09-25 | 2013-08-28 | 욱크하르트 리미티드 | 치환된 피페리디노페닐 옥사졸리디논 |
| TWI397418B (zh) | 2006-10-10 | 2013-06-01 | Otsuka Pharma Co Ltd | 抗憂鬱劑 |
| RU2009118935A (ru) | 2006-10-20 | 2010-11-27 | Мерк энд Ко., Инк. (US) | Земещенные имидазолы в качестве модуляторов подтипа 3 бомбезиновых рецепторов |
| HUE029188T2 (en) | 2007-03-12 | 2017-03-28 | Ym Biosciences Australia Pty | Phenylamino-pyrimidine compounds and their use |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| TW200902019A (en) | 2007-04-26 | 2009-01-16 | Ono Pharmaceutical Co | Dicyclic heterocyclic compound |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| US8431608B2 (en) | 2007-08-17 | 2013-04-30 | Icagen Inc. | Heterocycles as potassium channel modulators |
| EP2193119B1 (en) | 2007-08-27 | 2014-01-01 | Abbvie Deutschland GmbH & Co. KG | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators |
| ES2602577T3 (es) | 2008-03-11 | 2017-02-21 | Incyte Holdings Corporation | Derivados de azetidina y ciclobutano como inhibidores de JAK |
| US8613951B2 (en) | 2008-06-16 | 2013-12-24 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same |
| CN102256966B (zh) * | 2008-10-17 | 2016-02-10 | 白头生物医学研究所 | 可溶性mTOR复合物和其调节剂 |
| WO2010146172A2 (en) | 2009-06-19 | 2010-12-23 | Lek Pharmaceuticals D.D. | NEW SYNTHETIC ROUTE FOR THE PREPARATION OF α-AMINO BORONIC ACID DERIVATIVES VIA SUBSTITUTED ALK-1-YNES |
| WO2011012283A1 (en) * | 2009-07-30 | 2011-02-03 | University Of Zurich | Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event |
| EA201201052A1 (ru) | 2010-01-29 | 2013-02-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Замещенные нафтиридины и их применение в качестве ингибиторов киназы syk |
| MY177250A (en) * | 2010-06-30 | 2020-09-10 | Fujifilm Corp | Novel nicotinamide derivative or salt thereof |
| CN102464701B (zh) | 2010-11-08 | 2015-10-21 | 上海医药工业研究院 | 一类新型化合物、其制备方法及用途 |
| WO2012076063A1 (en) | 2010-12-10 | 2012-06-14 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
| WO2012113847A1 (en) | 2011-02-25 | 2012-08-30 | Lonza Ltd | Branched linker for protein drug conjugates |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| WO2013052393A1 (en) | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| EP2589383A1 (en) * | 2011-11-06 | 2013-05-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin | FKBP subtype-specific rapamycin analogue for use in treatment of diseases |
| WO2013142229A1 (en) | 2012-03-19 | 2013-09-26 | President And Fellows Of Harvard College | Designing novel peptides for inducing fibronectin matrix assembly |
| US9790176B2 (en) | 2012-08-06 | 2017-10-17 | Pitney Pharmaceuticals Pty Limited | Compounds for the treatment of mTOR pathway related diseases |
| WO2014127052A1 (en) | 2013-02-13 | 2014-08-21 | Zondlo Neal | Perfluoro-tert-butyl hydroxyproline |
| WO2014145852A2 (en) | 2013-03-15 | 2014-09-18 | Knopp Biosciences Llc | Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators |
| WO2014201111A1 (en) | 2013-06-14 | 2014-12-18 | The Brigham And Women's Hospital, Inc. | Treatment of mtor hyperactive related diseases and disorders |
| EP3191116B1 (en) * | 2014-09-12 | 2020-11-25 | The Whitehead Institute for Biomedical Research | Methods of identifying modulators of sestrin-gator2 interaction and use of same to modulate mtorc1 |
| SI3364958T1 (sl) * | 2015-10-23 | 2023-05-31 | Navitor Pharmaceuticals, Inc. | Modulatorji interakcije sestrina in gator2 ter njihova uporaba |
| WO2017083823A1 (en) | 2015-11-13 | 2017-05-18 | Brandeis University | Mtor inhibitors and methods of use thereof |
| AU2017252563B2 (en) | 2016-04-21 | 2022-07-21 | Baylor College Of Medicine | Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction |
| WO2018200625A1 (en) | 2017-04-26 | 2018-11-01 | Navitor Pharmaceuticals, Inc. | Modulators of sestrin-gator2 interaction and uses thereof |
| JP2021512920A (ja) | 2018-02-08 | 2021-05-20 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 耳鳴、急性感音性難聴、メニエール病、トゥレット症候群、注意欠陥多動性障害、および嗜癖の治療における（１ｓ，３ｓ）−３−アミノ−４−（ジフルオロメチリデン）シクロペンタン−１−カルボン酸および（ｓ）−３−アミノ−４−（ジフルオロメチルエニル）シクロペンタ−１−エン−１−カルボン酸の使用 |
| EP3870158A4 (en) | 2018-10-24 | 2022-08-10 | Navitor Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
| US10926803B2 (en) | 2019-07-17 | 2021-02-23 | GM Global Technology Operations LLC | Four rail front crush structure with load dissemination into eight element support structure |
| TWI870497B (zh) | 2019-11-01 | 2025-01-21 | 美商奈維特製藥公司 | 使用mtorc1調節劑的治療方法 |
| JP6689441B1 (ja) | 2019-11-01 | 2020-04-28 | エヌ・ティ・ティ・コミュニケーションズ株式会社 | 電子マネー管理システムおよび電子マネー管理方法 |
-
2018
- 2018-04-25 WO PCT/US2018/029288 patent/WO2018200625A1/en not_active Ceased
- 2018-04-25 US US15/962,123 patent/US10912750B2/en active Active
- 2018-04-25 TW TW107114086A patent/TWI776886B/zh active
- 2018-04-25 ES ES18791427T patent/ES3040534T3/es active Active
- 2018-04-25 EP EP25169183.8A patent/EP4556069A3/en active Pending
- 2018-04-25 CA CA3061611A patent/CA3061611A1/en active Pending
- 2018-04-25 JP JP2019558443A patent/JP7179015B2/ja active Active
- 2018-04-25 AU AU2018258355A patent/AU2018258355B2/en active Active
- 2018-04-25 CN CN202310282338.XA patent/CN116370448A/zh active Pending
- 2018-04-25 CN CN201880039788.3A patent/CN110809467B/zh active Active
- 2018-04-25 EP EP18791427.0A patent/EP3615019B1/en active Active
-
2020
- 2020-11-30 US US17/106,584 patent/US11679090B2/en active Active
-
2023
- 2023-05-01 US US18/141,834 patent/US12427130B2/en active Active
-
2024
- 2024-08-30 AU AU2024216489A patent/AU2024216489A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517707A5 (enExample) | ||
| JP2018538248A5 (enExample) | ||
| JP2013532652A5 (enExample) | ||
| JP2011529918A5 (enExample) | ||
| JP2019520344A5 (enExample) | ||
| JP2020507589A5 (enExample) | ||
| JP2006505543A5 (enExample) | ||
| JP2010506854A5 (enExample) | ||
| JP2007529421A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2011529964A5 (enExample) | ||
| JP2019529444A5 (enExample) | ||
| JP2007527919A5 (enExample) | ||
| JP2008535903A5 (enExample) | ||
| JP2013515074A5 (enExample) | ||
| JP2012530779A5 (enExample) | ||
| JP2019518050A5 (enExample) | ||
| JP2018524304A5 (enExample) | ||
| RU2018127728A (ru) | Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич | |
| RU2010119458A (ru) | 1,3,5-тризамещенное производное триазола | |
| JP2019500387A5 (enExample) | ||
| JP2020533352A5 (enExample) | ||
| JP2018527301A5 (ja) | アジリジン含有ｄｎａアルキル化剤 | |
| JP2015536997A5 (enExample) | ||
| JPWO2023099623A5 (enExample) |